person · Reporting owner
Taylor Andrew Lawrence
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Motus GI Holdings, Inc.MOTS · Entity 93100 | Chief Financial Officer | February 10, 2022 | February 11, 2022 |
| Orchestra BioMed Holdings, Inc.OBIO · Entity 434 | Chief Financial Officer | August 26, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Motus GI Holdings, Inc.
Report date February 10, 2022 · Filed February 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 230,682 |
Reported balance
After 2022-02-10 transaction · row 1
1 source rowRow 1 · 2022-02-10 · Grant · Acquired 95,000 · Balance 230,682 F1: On February 10, 2022, Reporting Person was granted 95,000 Common Stock restricted stock units. The restricted stock units vest in a series of twelve (12) successive substantially equal quarterly installments, with the first installment vesting on May 1, 2022 and continuing the first day of each third month thereafter. Each restricted stock unit represents a contingent right to receive one share of Common Stock. The restricted stock units award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan") |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-02-10 | Direct | 95,000 |
Reported balance
After 2022-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-10 · Grant · Acquired 95,000 · Balance 95,000 F2: The option award was made in accordance with the terms of the 2016 Plan. The option vests in a series of twelve (12) successive substantially equal quarterly installments, with the first installment vesting on May 1, 2022 and continuing the first day of each third month thereafter. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 10, 2022, Reporting Person was granted 95,000 Common Stock restricted stock units. The restricted stock units vest in a series of twelve (12) successive substantially equal quarterly installments, with the first installment vesting on May 1, 2022 and continuing the first day of each third month thereafter. Each restricted stock unit represents a contingent right to receive one share of Common Stock. The restricted stock units award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan")
F2: The option award was made in accordance with the terms of the 2016 Plan. The option vests in a series of twelve (12) successive substantially equal quarterly installments, with the first installment vesting on May 1, 2022 and continuing the first day of each third month thereafter. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan.
Orchestra BioMed Holdings, Inc.
Report date August 26, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 589,989 |
Reported balance
After 2026-08-26 transaction · row 1
1 source rowRow 1 · 2026-08-26 · Tax withholding · Disposed 3,076 · Balance 589,989 F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2026 Filed Aug 28, 2026 20:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share | 3,076 | $5.26 | $16,179.76 |
DisclosureSEC source: 0001104659-26-103210 · tm2624220-3_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589,989 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share | 36,352 | $4.02 | $146,135.04 |
DisclosureSEC source: 0001104659-26-073476 · tm2617747-2_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 593,065 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share | 3,076 | $3.98 | $12,242.48 |
DisclosureSEC source: 0001104659-26-068278 · tm2616050-2_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 629,417 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:01 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share | 181,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-015320 · tm266316-2_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 632,493 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 25% of the shares will vest 18 months after February 12, 2026 (the "Issue Date"), (ii) 25% of the shares will vest 24 months after the Issue Date, (iii) 25% of the shares will vest 30 months after the Issue Date and (iv) 25% of the shares will vest 36 months after the Issue Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 23:55 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share | 3,452 | $4.31 | $14,878.12 |
DisclosureSEC source: 0001104659-26-000272 · tm261746-3_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,493 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:17 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share | 8,670 | $4.67 | $40,488.90 |
DisclosureSEC source: 0001104659-25-120668 · tm2533361-2_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454,945 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:05 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share | 3,071 | $5.35 | $16,429.85 |
DisclosureSEC source: 0001104659-25-116432 · tm2532314-2_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 463,615 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 21:30 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share | 16,102 | $2.46 | $39,610.92 |
DisclosureSEC source: 0001104659-25-091743 · tm2526559-2_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,686 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| August 25, 2025 Filed Aug 25, 2025 23:01 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share | 2,000 | $2.55 | $5,100.00 |
DisclosureSEC source: 0001104659-25-082633 · tm2524324-1_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,788 Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 23:18 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-075789 · tm2523004-10_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,788 F1 · shares: Represents an award of restricted stock units ("RSUs") to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 33.33% of the shares will vest 24 months after the Grant Date, (ii) 33.33% of the shares will vest 30 months after the Grant Date, and (iii) 33.34% of the shares will vest 36 months after the Grant Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:43 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share ("Common Stock") | 28,172 | $3.14 | $88,460.08 |
DisclosureSEC source: 0001104659-25-059418 · tm2517997-2_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,788 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| April 04, 2025 Filed Apr 5, 2025 01:37 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 84,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-032330 · tm2511637-1_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,960 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 33.33% of the shares will vest 24 months after April 4, 2025 (the "Issue Date"), (ii) 33.33% of the shares will vest 30 months after the Issue Date, and (iii) 33.34% of the shares will vest 36 months after the Issue Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 13:30 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share | 1,000 | $4.83 | $4,830.00 |
DisclosureSEC source: 0001104659-24-130521 · tm2431687-1_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,960 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.81 to $4.89. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share | 34,403 | $5.03 | $173,047.09 |
DisclosureSEC source: 0001104659-24-128431 · tm2431042-1_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,960 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. F1 · shares: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. Read SEC document |
| May 08, 2024 Filed May 10, 2024 21:18 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-059991 · tm2414108-1_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,363 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as follows: (i) 15,000 RSUs will vest on May 20, 2025, and (ii) the remaining 85,000 RSUs will vest in equal installments on August 20, 2025, November 20, 2025, December 20, 2025, May 20, 2026, August 20, 2026, November 20, 2026, March 25, 2027, May 20, 2027, August 20, 2027, November 20, 2027, March 25, 2028 and May 20, 2028, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 21:12 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 278,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-083501 · tm2321855-8_4seq1.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,363 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 34% of the shares will vest on the 18-month anniversary of June 6, 2023 (the "Vesting Commencement Date"), (ii) 33% the shares will vest on the two-year anniversary of the Vesting Commencement Date, and (iii) 33% the shares will vest on the three-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 17:15 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001493152-22-004082 · ownership.xml · derivative · entry 2 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock, par value $0.0001 per share · 95,000 shares Expires 2032-02-10 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the 2016 Plan. The option vests in a series of twelve (12) successive substantially equal quarterly installments, with the first installment vesting on May 1, 2022 and continuing the first day of each third month thereafter. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 17:15 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-004082 · ownership.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,682 F1 · shares: On February 10, 2022, Reporting Person was granted 95,000 Common Stock restricted stock units. The restricted stock units vest in a series of twelve (12) successive substantially equal quarterly installments, with the first installment vesting on May 1, 2022 and continuing the first day of each third month thereafter. Each restricted stock unit represents a contingent right to receive one share of Common Stock. The restricted stock units award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan") Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 08:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | PurchaseCommon Stock, par value $0.0001 per share | 2,000 | $0.51 | $1,021.20 |
DisclosureSEC source: 0001213900-21-061014 · ownership.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,682 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:15 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-21-010585 · ownership.xml · derivative · entry 2 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock, par value $0.0001 per share · 60,000 shares Expires 2031-02-17 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the 2016 Plan. The option vests in substantially equal quarterly installments over three years commencing from the date of grant. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:15 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-010585 · ownership.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,682 F1 · shares: On February 17, 2021, Reporting Person was granted 60,000 Common Stock restricted stock units. The restricted stock units vest in substantially equal quarterly installments over three years commencing on February 17, 2021. Each restricted stock unit represents a contingent right to receive one share of Common Stock. The restricted stock units award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 09:02 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | PurchaseCommon Stock, par value $0.0001 per share | 1,000 | $1.08 | $1,080.00 |
DisclosureSEC source: 0001213900-20-041938 · ownership.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,682 Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 17:33 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001213900-20-037014 · ownership.xml · derivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock, par value $0.0001 per share · 85,000 shares Expires 2030-11-11 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| November 11, 2020 Filed Feb 19, 2021 16:15 UTC Amendment | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 78,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001213900-21-010584 · ownership.xml · derivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock, par value $0.0001 per share · 78,000 shares Expires 2030-11-11 F1 · security: The number of options granted has been reduced from 85,000 to 78,000 to correct an administrative error. F2 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 16:34 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001213900-20-014846 · ownership.xml · derivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock, par value $0.0001 per share · 90,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:42 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 46,098 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001213900-20-002939 · ownership.xml · derivative · entry 2 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,098 Underlying: Common Stock, par value $0.0001 per share · 46,098 shares Expires 2030-02-06 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the 2016 Plan. The option vests in substantially equal quarterly installments over three years commencing from the date of grant. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:42 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 46,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-002939 · ownership.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,682 F1 · shares: On February 6, 2020, Reporting Person was granted 46,098 Common Stock restricted stock units. The restricted stock units vest in substantially equal quarterly installments over three years commencing on February 6, 2020. Each restricted stock unit represents a contingent right to receive one share of Common Stock. The restricted stock units award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 17:02 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantStock Option (right to buy) · Derivative | 70,753 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001615774-19-002644 · s116122_form4.xml · derivative · entry 2 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,753 Underlying: Common Stock, par value $0.0001 per share · 70,753 shares Expires 2029-02-13 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). The option vests in substantially equal quarterly installments over three years commencing from the date of grant. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 17:02 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | GrantCommon Stock, par value $0.0001 per share | 23,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-19-002644 · s116122_form4.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,584 F1 · shares: On February 13, 2019, the Reporting Person was granted 23,584 Common Stock restricted stock units, which vest in substantially equal quarterly installments over four years commencing on February 13, 2019. Each restricted stock unit represents a contingent right to receive one share of Common Stock. Read SEC document |
| December 24, 2018 Filed Dec 26, 2018 17:10 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | PurchaseCommon Stock, par value $0.0001 per share | 1,000 | $2.70 | $2,700.00 |
DisclosureSEC source: 0001615774-18-014980 · s114871_form4.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The securities were purchased pursuant to an underwritten public offering by the Issuer. The offering closed on December 24, 2018. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:05 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | PurchaseCommon Stock, par value $0.0001 per share | 2,000 | $5.00 | $10,000.00 |
DisclosureSEC source: 0001493152-18-002419 · form4.xml · nonDerivative · entry 1 Taylor Andrew Lawrence · CIK 0001723889 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The securities were purchased pursuant to an underwritten public offering by the Issuer. The offering closed on February 16, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.